Pharmaceutical Industry Veteran Joins Neuvivo

Neuvivo, a biopharmaceutical company developing breakthrough novel therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, has appointed Mark Henderson, PhD, as the company’s new Vice President of Manufacturing.
 
In this role, Dr. Henderson will oversee manufacturing, quality assurance and drug formulation, including for NP001—Neuvivo’s investigational treatment for ALS—which has been granted Orphan Drug and Fast Track Designations by the FDA.
 
“Dr. Henderson’s industry expertise and innovative mindset will be crucial in establishing our manufacturing processes and maintaining our rigorous quality standards,” said Ari Azhir, PhD, founder and CEO of Neuvivo. “As we advance NP001, Dr. Henderson’s leadership will be pivotal in our efforts to improve care for those living with ALS.”
 
Henderson brings over 25 years of experience in pharmaceutical facility operations, quality assurance and manufacturing. Working across both global biotechnology companies and a private, clinical-stage startup, he has held leadership roles in early-stage manufacturing and process development for well-established groups as well as building teams from the ground up.
 
Henderson has authored components of multiple regulatory filings, including multiple New Drug Applications (NDAs) (Kuvan and Firdapse), Biologics License Applications (BLAs) (Naglazyme, Vimizim and Palynziq) and marketing authorization applications (MAAs) (Aldurazyme, Naglazyme, Vimizim, Kuvan and Firdapse).
 
“I’ve devoted my career to producing new treatments for those in need, and I’m energized by the thought of using my expertise to help bring NP001 to the ALS community,” said Henderson.